Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iloprost in Septic Shock Induced Endotheliopathy
NCT04123444Phase 3Completed
- Sponsor
- Jakob Stensballe
- Start
- Oct 2019
- Primary completion
- Jun 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in septic shock comparing Iloprost with Placebo (2 arms). Primary endpoint: Modified Sequential Organ Failure Assessment at 90 days. Started Oct 2019; status: completed.
02
Drugs
iloprost
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT04123444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04123444.